Cervical Priming With Misoprostol Prior to Operative Hysteroscopy

Samsung Medical Center

Status and phase: Completed; Phase 3

Conditions: Cervical Ripening

Treatments: Drug: Misoprostol

Study type: Interventional

Funder types: Other

Identifiers

NCT01024270

2008-06-035

Details and patient eligibility

About

The primary outcome measure in this study was the preoperative cervical width after misoprostol administration. The secondary outcomes were duration of cervical dilatation, up to Hegar number 10, complications during cervical dilation and the hysteroscopy, and misoprostol associated side effects. The cervical width was assessed by performing cervical dilatation, starting with a number 10 Hegar dilator and subsequently inserting smaller Hegar dilatators until the dilator could pass through the internal os without resistance. The largest one that could be passed was recorded as the initial cervical width.

The mean cervical diameter, after oral and vaginal misoprostol of 400 μg, has been reported to be 6.0 ± 1.5 mm and 7.3 ± 1.6 mm, respectively 4. The investigators hypothesized that equivalence was of clinical significance if the difference in the initial cervical width was less than 1 mm among groups with the standard deviation of the initial cervical width of 1.6 mm. The estimated sample size was 47 patients in each group; this would be able to detect an equivalent effect in the groups with a power of 80% and a type 1 error (a) of 0.017. Data are expressed as the mean ± SD (standard deviation) or median with range or as the number (%) of cases.

Enrollment: 141 patients

Sex: Female

Ages: 20 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Symptomatic patients that were suspected as having intrauterine pathology such as submucosal myoma, endometrial polyps or other endometrial pathological findings based on the transvaginal ultrasound were enrolled.
• women who are more than 20 years of age with having sexual contact history
• women whose last menstrual period are within the last two months.

Exclusion criteria

• Post menopausal women
• any evidence of a contraindication or allergy to PGs
• any sign of genital infection, history of cervical surgery, endometrial lesions with suspected endo- or exocervical lesions that could affect the cervical resistance or patients that were not candidates for surgery.

Trial design

141 participants in 1 patient group

sublingual, oral and vaginal administration of misoprostol

Experimental group

Treatment:

Drug: Misoprostol